BrainomixAIBrainomix extends Series C to £18.8m as Oxford AI imaging spinout pushes into the USOxford-based Brainomix has added £4.8 million (approximately $6.5m/€5.5m) to its Series C financing, bringing the total round to £18.8 million ($25.4m/€21.5m) and providing fresh capital to accelerate … more ➔
BioNTech SECancer vaccinationEarly BioNTech mRNA breast cancer trial delivers surprise in longtime disease controlA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. … more ➔
CollaborationAngelini partners with Quiver on AI-driven discovery in genetic epilepsiesItaly’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including … more ➔
Flu vaccinesEurope accelerates next-generation flu vaccines with €225m innovation procurement pushA group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the … more ➔
Unsplash+Clinical DataMoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s BimzelxMost inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market. more ➔
financingSyndex Bio raises $15.5M seed and unveils mcPCR platform for DNA methylation analysisCambridge, UK-based Syndex Bio has announced on Monday the introduction of its proprietary mcPCR™ (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, … more ➔
Neurological disordersLario Therapeutics wins $2.4m grants to advance calcium channel drugs for Parkinson’s and PTSDEdinburgh-based Lario Therapeutics has received $2.4 million (approximately €2m) in grant funding from The Michael J. Fox Foundation and Wellcome to expand its drug discovery platform targeting voltage-gated … more ➔
adobe.stock.com - ipopbaAlzheimerJ&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clearA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties … more ➔
COPDForbion and Sanofi drive $75M investment in COPD biotech AltesaForbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter. more ➔
Unsplash+Drug discoveryNovartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural ProductsCalifornia-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide … more ➔
Brainomix
BioNTech SE
Unsplash+
adobe.stock.com - ipopba
Unsplash+